Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38661093 | 0.87 | MAPK1 (0.45) | GPR119MAPK1CYP2D6CYP2C9GRM1 | |
| SCHEMBL23982034 | 0.87 | GPR119 (0.43) | GPR119MAPK1KDM4EMAPT | |
| SCHEMBL940218 | 0.87 | MAPK1 (0.50) | GPR119MAPK1KDM4E | |
| SCHEMBL28225677 | 0.87 | MAPK1 (0.50) | GPR119MAPK1KDM4E | |
| SCHEMBL5651780 | 0.87 | MAPK1 (0.50) | GPR119MAPK1KDM4E | |
| SCHEMBL19745334 | 0.87 | MAPK1 (0.50) | GPR119MAPK1KDM4E | |
| Hydrochloric Acid SCHEMBL28503227 | 0.85 | MAPK1 (0.49) | GPR119MAPK1KDM4E | |
| SCHEMBL30273306 | 0.82 | STS (0.40) | GPR119MAPK1MEN1KMT2AKDM4E | |
| SCHEMBL23981737 | 0.82 | STS (0.40) | GPR119MAPK1MEN1KMT2AKDM4E | |
| SCHEMBL15365495 | 0.81 | ESR2 (0.44) | GPR119MAPK1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-117794525-A | Anticancer compounds | 加利福尼亚大学董事会 | 2024-03-29 | — | — | CN | disclosed |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | UNIV OREGON HEALTH & SCIENCE (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | UNIV OREGON HEALTH & SCIENCE (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | UNIV OREGON HEALTH & SCIENCE (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115996908-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2023-04-21 | — | — | CN | disclosed |
| WO-2021222858-A1 | ANTAGONISTS OF GPR39 PROTEIN | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-107253963-A | Pyridone and azepine pyridinone compounds and application method | 吉利德康涅狄格有限公司 | 2017-10-17 | — | — | CN | disclosed |
| CN-107011348-A | It is used as the heteroaryl pyridines ketone and azepine pyridinone compounds of the inhibitor of BTK activity | 霍夫曼-拉罗奇有限公司 | 2017-08-04 | — | — | CN | disclosed |
| CN-103038233-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2017-06-20 | — | — | CN | disclosed |
| CN-104125959-B | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of BTK activity | 霍夫曼-拉罗奇有限公司 | 2017-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | GPR119 3/4885MAPK1 3174/4885MEN1 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.